RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Chugai Pharmaceutical Co Stock

Chugai Pharmaceutical Co Revenue 2024

Chugai Pharmaceutical Co Revenue

1.14 T JPY

Ticker

4519.T

ISIN

JP3519400000

WKN

857216

In 2024, Chugai Pharmaceutical Co's sales reached 1.14 T JPY, a 2.55% difference from the 1.11 T JPY sales recorded in the previous year.

The Chugai Pharmaceutical Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2026e1.2356,58
2025e1.1759,93
2024e1.1461,30
20231.1162,87
20221.2662,19
2021166,22
20200.7965,25
20190.6961,42
20180.5854,66
20170.5352,42
20160.4949,58
20150.551,84
20140.4652,71
20130.4255,87
20120.3957,13
20110.3757,83
20100.3857,20
20090.4355,04
20080.3361,15
20070.3460,18
20060.3359,19
20050.3363,49
20040.2962,15

Chugai Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Chugai Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chugai Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chugai Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Chugai Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Chugai Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Chugai Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chugai Pharmaceutical Co’s growth potential.

Chugai Pharmaceutical Co Revenue, EBIT and net profit per share

DateChugai Pharmaceutical Co RevenueChugai Pharmaceutical Co EBITChugai Pharmaceutical Co Net Income
2026e1.23 T undefined0 undefined429.48 B undefined
2025e1.17 T undefined0 undefined394.56 B undefined
2024e1.14 T undefined0 undefined382.88 B undefined
20231.11 T undefined444.93 B undefined325.47 B undefined
20221.26 T undefined533.95 B undefined374.43 B undefined
2021999.76 B undefined428.24 B undefined303 B undefined
2020786.95 B undefined302.18 B undefined214.73 B undefined
2019686.18 B undefined214.51 B undefined157.56 B undefined
2018579.79 B undefined124.32 B undefined92.49 B undefined
2017534.2 B undefined98.93 B undefined72.71 B undefined
2016491.78 B undefined76.88 B undefined53.59 B undefined
2015498.84 B undefined86.78 B undefined61.13 B undefined
2014461.11 B undefined75.86 B undefined50.98 B undefined
2013423.65 B undefined78.74 B undefined50.9 B undefined
2012391.22 B undefined76.41 B undefined48.21 B undefined
2011373.52 B undefined62.43 B undefined35.23 B undefined
2010379.51 B undefined66.24 B undefined41.43 B undefined
2009428.95 B undefined82.62 B undefined56.63 B undefined
2008326.94 B undefined51.56 B undefined39.26 B undefined
2007344.81 B undefined66.7 B undefined40.06 B undefined
2006326.11 B undefined58.35 B undefined38.42 B undefined
2005327.16 B undefined79.17 B undefined53.41 B undefined
2004294.67 B undefined51.5 B undefined34.03 B undefined

Chugai Pharmaceutical Co stock margins

The Chugai Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chugai Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chugai Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Chugai Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Chugai Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Chugai Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Chugai Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chugai Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chugai Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chugai Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Chugai Pharmaceutical Co Margin History

Chugai Pharmaceutical Co Gross marginChugai Pharmaceutical Co Profit marginChugai Pharmaceutical Co EBIT marginChugai Pharmaceutical Co Profit margin
2026e62.87 %0 %34.78 %
2025e62.87 %0 %33.84 %
2024e62.87 %0 %33.59 %
202362.87 %40.03 %29.29 %
202262.19 %42.39 %29.72 %
202166.22 %42.83 %30.31 %
202065.25 %38.4 %27.29 %
201961.42 %31.26 %22.96 %
201854.66 %21.44 %15.95 %
201752.42 %18.52 %13.61 %
201649.58 %15.63 %10.9 %
201551.84 %17.4 %12.25 %
201452.71 %16.45 %11.06 %
201355.87 %18.59 %12.01 %
201257.13 %19.53 %12.32 %
201157.83 %16.71 %9.43 %
201057.2 %17.45 %10.92 %
200955.04 %19.26 %13.2 %
200861.15 %15.77 %12.01 %
200760.18 %19.34 %11.62 %
200659.19 %17.89 %11.78 %
200563.49 %24.2 %16.33 %
200462.15 %17.48 %11.55 %

Chugai Pharmaceutical Co Aktienanalyse

What does Chugai Pharmaceutical Co do?

Chugai Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1925. It is headquartered in Tokyo and employs over 7,500 employees worldwide. Chugai is one of the largest pharmaceutical companies in Japan and has become a global company with a strong research and development department in recent decades. The business model of Chugai is based on the development and production of drugs for various medical conditions, with a focus on cancer therapy. However, Chugai also has drugs for other medical conditions in its portfolio, such as rheumatism, asthma, and diabetes. The company specializes in research and development of biotechnological therapeutics and has focused on the study of biological agents. Chugai's goal is to improve people's lives and enhance patient care. Chugai is divided into several business units, each focusing on different areas of therapy. One of these areas is oncology. Chugai has a strong range of oncology products, for which it is a market leader in Japan. These include Avastin, an anti-angiogenesis drug for the treatment of colorectal, breast, lung, and kidney cancer, as well as Herceptin for the treatment of breast and gastric cancer, and Tarceva for treating bronchial carcinomas. Another important business area of Chugai is rheumatology. Here, Chugai offers various products such as Actemra, a monoclonal antibody against the interleukin-6 receptor used in rheumatoid arthritis, as well as Rituxan, an antibody against the CD20 antigen used in the treatment of lymphomas. In addition to drug development and manufacturing, Chugai also conducts research and development in the field of diagnostics. This is an important complement to the company's therapeutic portfolio. Chugai develops diagnostics to improve disease diagnosis. Another important area of Chugai is the outsourcing of research and development services. Chugai collaborates with many international pharmaceutical companies, offering its expertise and infrastructure in the development of new drugs. Chugai Pharmaceuticals is a significant player in global healthcare and aims to establish itself as a leading company in biological and cellular preparation research. The company invests significant resources in the exploration of new technologies to ensure sustainable therapy options. Chugai Pharmaceuticals has built a strong presence in the global market in recent years and will continue to play an important role in the future. Chugai Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Chugai Pharmaceutical Co's Sales Figures

The sales figures of Chugai Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Chugai Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Chugai Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Chugai Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Chugai Pharmaceutical Co stock

How much revenue did Chugai Pharmaceutical Co generate this year?

Chugai Pharmaceutical Co has achieved a revenue of 1.14 T JPY this year.

How much was the turnover of the company Chugai Pharmaceutical Co compared to the previous year?

The revenue of Chugai Pharmaceutical Co has increased by 2.55% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Chugai Pharmaceutical Co?

The revenue of Chugai Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Chugai Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Chugai Pharmaceutical Co so important for investors?

The revenue of Chugai Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Chugai Pharmaceutical Co pay?

Over the past 12 months, Chugai Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 1.12 %. For the coming 12 months, Chugai Pharmaceutical Co is expected to pay a dividend of 93.2 JPY.

What is the dividend yield of Chugai Pharmaceutical Co?

The current dividend yield of Chugai Pharmaceutical Co is 1.12 %.

When does Chugai Pharmaceutical Co pay dividends?

Chugai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Chugai Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 93.2 JPY are expected. This corresponds to a dividend yield of 1.31 %.

In which sector is Chugai Pharmaceutical Co located?

Chugai Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chugai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chugai Pharmaceutical Co from 3/1/2025 amounting to 41 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Chugai Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Chugai Pharmaceutical Co in the year 2023?

In the year 2023, Chugai Pharmaceutical Co distributed 78 JPY as dividends.

In which currency does Chugai Pharmaceutical Co pay out the dividend?

The dividends of Chugai Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Chugai Pharmaceutical Co

Our stock analysis for Chugai Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chugai Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.